J. Nam

13.7k total citations · 1 hit paper
57 papers, 3.0k citations indexed

About

J. Nam is a scholar working on Rheumatology, Hematology and Immunology. According to data from OpenAlex, J. Nam has authored 57 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Rheumatology, 18 papers in Hematology and 14 papers in Immunology. Recurrent topics in J. Nam's work include Rheumatoid Arthritis Research and Therapies (50 papers), Systemic Lupus Erythematosus Research (23 papers) and Autoimmune and Inflammatory Disorders Research (18 papers). J. Nam is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (50 papers), Systemic Lupus Erythematosus Research (23 papers) and Autoimmune and Inflammatory Disorders Research (18 papers). J. Nam collaborates with scholars based in United Kingdom, Netherlands and France. J. Nam's co-authors include Robert Landewé, Paul Emery, Sofía Ramiro, Maya H Buch, Désirée van der Heijde, C. Gaujoux-Viala, Laure Gossec, E. Hensor, Kevin Winthrop and Ronald van Vollenhoven and has published in prestigious journals such as The Lancet, PLoS ONE and Annals of the Rheumatic Diseases.

In The Last Decade

J. Nam

54 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

2014 536 citations Sofía Ramiro, C. Gaujoux-Viala et al. Annals of the Rheumatic Diseases profile →

Peers

Countries citing papers authored by J. Nam

Since Specialization

Citations

This map shows the geographic impact of J. Nam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Nam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Nam more than expected).

Fields of papers citing papers by J. Nam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Nam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Nam. The network helps show where J. Nam may publish in the future.

Co-authorship network of co-authors of J. Nam

This figure shows the co-authorship network connecting the top 25 collaborators of J. Nam. A scholar is included among the top collaborators of J. Nam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Nam. J. Nam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Neither ultrasound synovitis nor clinical-ultrasound phenotypes of established rheumatoid arthritis predict response to targeted therapy 2025 ·Lara D. Veeken ·John Fitton, Andrew Melville, Andrea Di Matteo, J. Nam, Shouvik Dass, Benazir Saleem, (unknown), Paul Emery, Richard J. Wakefield, E. Hensor, Maya H Buch	0
2	A multivariable prediction model to identify anti-CCP positive people in those with non-specific musculoskeletal symptoms in primary care 2024 ·Lara D. Veeken ·Heidi J. Siddle, Michelle Wilson, J. Nam, Leticia Garcia‐Montoya, (unknown), Kulveer Mankia, Paul Emery, E. Hensor	1
3	P08 Long-term comparative efficacy and safety of risdiplam versus nusinersen in children with Type 1 spinal muscular atrophy (SMA) 2023 ·Neuromuscular Disorders ·Gautam Sajeev, Rachel Evans, Neil Hawkins, (unknown), David A. Scott, J. Nam, S.S. Sutherland, (unknown)	2
4	POS0947 SUBCLINICAL SYNOVITIS IN ANTI-CCP POSITIVE INDIVIDUALS AT-RISK OF RA: HOW LIKELY IS IT TO RESOLVE? 2023 ·Annals of the Rheumatic Diseases ·Leticia Garcia‐Montoya, (unknown), J. Nam, Andrea Di Matteo, (unknown), Rajib Chowdhury, Kulveer Mankia, Paul Emery	1
5	OP0124 A REDUCED ULTRASOUND SCANNING PROTOCOL OF 3 JOINTS BILATERALLY IMPROVES PREDICTION OF INFLAMMATORY ARTHRITIS PROGRESSION IN ANTI-CCP ANTIBODIES POSITIVE INDIVIDUALS WITH MUSCULOSKELETAL SYMPTOMS 2023 ·Annals of the Rheumatic Diseases ·Andrea Di Matteo, Enrico De Lorenzis, (unknown), J. Nam, Leticia Garcia‐Montoya, (unknown), (unknown), Paul Emery, Kulveer Mankia	1
6	THU0094 IN ACPA POSITIVE AT-RISK INDIVIDUALS WITHOUT CLINICAL ARTHRITIS, IS ULTRASOUND SUFFICIENTLY ACCURATE TO PREDICT PROGRESSION TO INFLAMMATORY ARTHRITIS? 2020 ·Annals of the Rheumatic Diseases ·(unknown), Kulveer Mankia, Andrea Di Matteo, Leticia Garcia‐Montoya, J. Nam, Paul Emery	5
7	Comparing Psoriatic Arthritis Low-field Magnetic Resonance Imaging, Ultrasound, and Clinical Outcomes: Data from the TICOPA Trial 2019 ·The Journal of Rheumatology ·Philip Helliwell, Laura C. Coates, (unknown), (unknown), Anna R. Moverley, Jane Freeston, J. Nam, Robin Waxman, Paul Emery, Philip G. Conaghan	13
8	Identification of a distinct imaging phenotype may improve the management of palindromic rheumatism 2018 ·Annals of the Rheumatic Diseases ·Kulveer Mankia, Maria Antonietta D’Agostino, Richard J. Wakefield, J. Nam, (unknown), Andrew J. Grainger, Paul Emery	24
9	Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis 2017 ·Annals of the Rheumatic Diseases ·J. Nam, Kaoru Takase-Minegishi, Sofía Ramiro, Katerina Chatzidionysiou, Josef S Smolen, Désirée van der Heijde, J. W. J. Bijlsma, Gerd R Burmester, Maxime Dougados, Marieke Voshaar, Ronald van Vollenhoven, Robert Landewé	183
10	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis 2017 ·Annals of the Rheumatic Diseases ·Sofía Ramiro, Alexandre Sepriano, Katerina Chatzidionysiou, J. Nam, Josef S Smolen, Désirée van der Heijde, Maxime Dougados, Ronald van Vollenhoven, J. W. J. Bijlsma, Gerd R Burmester, Marieke Voshaar, Louise Falzon, Robert Landewé	246
11	Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis 2017 ·Annals of the Rheumatic Diseases ·Katerina Chatzidionysiou, Sharzad Emamikia, J. Nam, Sofía Ramiro, Josef S Smolen, Désirée van der Heijde, Maxime Dougados, J. W. J. Bijlsma, Gerd R Burmester, (unknown), Ronald van Vollenhoven, Robert Landewé	228
12	Role of ultrasound imaging in individuals at risk of RA 2017 ·Best Practice & Research Clinical Rheumatology ·J. Nam, Maria Antonietta D’Agostino	10
13	Biologics in rheumatoid arthritis: where are we going? 2014 ·British Journal of Hospital Medicine ·(unknown), J. Nam, Paul Emery	8
14	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis breakdown → 2014 ·Annals of the Rheumatic Diseases ·Sofía Ramiro, C. Gaujoux-Viala, J. Nam, Josef S Smolen, Maya H Buch, Laure Gossec, Désirée van der Heijde, Kevin Winthrop, Robert Landewé	536
15	Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis 2014 ·Annals of the Rheumatic Diseases ·C. Gaujoux-Viala, J. Nam, Sofía Ramiro, Robert Landewé, Maya H Buch, Josef S Smolen, Laure Gossec	106
16	Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis 2014 ·Annals of the Rheumatic Diseases ·J. Nam, Sofía Ramiro, C. Gaujoux-Viala, Kaoru Takase, (unknown), Paul Emery, Laure Gossec, Robert Landewé, Josef S Smolen, Maya H Buch	266
17	A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial 2014 ·Annals of the Rheumatic Diseases ·J. Nam, Édith Villeneuve, E. Hensor, Richard J. Wakefield, Philip G. Conaghan, (unknown), Andrew Gough, Mark Quinn, Richard J. Reece, Sally Cox, Maya H Buch, Désirée van der Heijde, Paul Emery	54
18	Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study) 2013 ·Annals of the Rheumatic Diseases ·J. Nam, Édith Villeneuve, E. Hensor, Philip G. Conaghan, Helen Keen, Maya H Buch, Andrew Gough, (unknown), Philip Helliwell, Anne‐Maree Keenan, Ann W Morgan, Mark Quinn, Richard J. Reece, Désirée van der Heijde, Richard J. Wakefield, Paul Emery	122
19	Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA 2010 ·Annals of the Rheumatic Diseases ·J. Nam, Kevin Winthrop, Ronald van Vollenhoven, Karel Pavelká, Guido Valesini, E. Hensor, Gillian Worthy, Robert Landewé, Josef S Smolen, Paul Emery, Maya H Buch	284
20	Aspects of TNF inhibitor therapy in rheumatoid arthritis 2010 ·Modern Rheumatology ·J. Nam, Paul Emery	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact